Published by Becton Dickinson
BD ANNOUNCES FOURTH FISCAL QUARTER AND FULL YEAR 2021 RESULTS; ISSUES FISCAL YEAR 2022 GUIDANCE
FRANKLIN LAKES, NJ (November 4, 2021) - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for the fourth fiscal quarter and full fiscal year ended September 30, 2021.
• Fourth fiscal quarter revenues of $5.1 billion grew 7.3% on a reported basis or 5.9% on a currency-neutral basis.
• Fiscal 2021 full-year revenues of $20.2 billion grew 18.3% on a reported basis or 15.6% on a currency-neutral basis.
• Fourth fiscal quarter GAAP diluted earnings per share (EPS) increased 133.3% to $0.84; adjusted diluted EPS decreased 7.2% to $2.59.
• Fiscal 2021 full-year GAAP diluted EPS increased 152.8% to $6.85; adjusted diluted EPS increased 28.2% to $13.08.
• BD issues fiscal 2022 guidance of $19.3 to $19.5 billion in revenues and $12.30 to $12.50 adjusted diluted EPS; includes base business revenue growth of 5% to 6% on a currency-neutral basis with improved margin profile.
• BD announced its 50th consecutive year of dividend increases; dividend raised 4.8%
“Our strong performance in fiscal 2021 was driven by the extraordinary efforts of our global team and demonstrates the resilience of BD’s portfolio in even the most uncertain health care environments,” said Tom Polen, chairman, CEO and president of BD. “We also took a number of critical steps this year to lay the foundation for the next phase of our growth, which included strengthening our balance sheet and cash flows, increasing our investments into higher-growth spaces, and stepping up our pace of tuck-in M&A activity. With increasing momentum in our base business and a clear path to accelerate margin recovery in fiscal 2022 and beyond, we are well-positioned to deliver on our commitments and drive long-term growth and value for all stakeholders."